• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Prescott Group Capital Management, L.L.C. claimed ownership of 1,783,097 shares (SEC Form 3)

    8/11/25 12:51:44 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.

    (Last) (First) (Middle)
    1924 S UTICA AVE
    SUITE 1120

    (Street)
    TULSA OK 74104

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/31/2025
    3. Issuer Name and Ticker or Trading Symbol
    NATURES SUNSHINE PRODUCTS INC [ NATR ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, no par value 1,783,097(1) I See Footnote(2)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.

    (Last) (First) (Middle)
    1924 S UTICA AVE
    SUITE 1120

    (Street)
    TULSA OK 74104

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    PRESCOTT GROUP AGGRESSIVE SMALL CAP LP

    (Last) (First) (Middle)
    1924 S UTICA AVE, SUITE 1120

    (Street)
    TULSA OK 74104

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    PRESCOTT GROUP AGGRESSIVE SMALL CAP II LP

    (Last) (First) (Middle)
    1924 S UTICA AVE, SUITE 1120

    (Street)
    TULSA OK 74104

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    PRESCOTT GROUP AGGRESSIVE SMALL CAP MASTER FUND GP

    (Last) (First) (Middle)
    1924 S UTICA AVE, SUITE 1120

    (Street)
    TULSA OK 74104

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    FROHLICH PHIL

    (Last) (First) (Middle)
    1924 S UTICA AVE, SUITE 1120

    (Street)
    TULSA OK 74104

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. The filing of this Form 3 shall not be construed as an admission that Prescott Group Capital Management, L.L.C. ("Prescott Capital") or Phil Frohlich, the managing member of Prescott Capital, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the Common Stock, no par value (the "Common Stock"), of Nature's Sunshine Products, Inc. (the "Issuer") held by Prescott Group Aggressive Small Cap Master Fund, G.P. (the "Master Fund") for the accounts of Prescott Group Aggressive Small Cap, L.P. and Prescott Group Aggressive Small Cap II, L.P. (together, the "Small Cap Funds"). Pursuant to Rule 16a-1, both Prescott Capital and Mr. Frohlich disclaim such beneficial ownership.
    2. This Form 3 relates to shares of Common Stock of the Issuer held in the account of the Master Fund, of which the Small Cap Funds are general partners. Prescott Capital serves as the general partner and investment manager of the Small Cap Funds and may direct the Small Cap Funds. The Master Fund holds the shares of Common Stock for the accounts of the Small Cap Funds. Prescott Capital receives a portion of the profits in the way of a capital allocation from, and owns a partnership interest in, the Small Cap Funds. Phil Frohlich reports the Common Stock held indirectly by Prescott Capital because, as the managing member of Prescott Capital at the time of purchase, he controlled the disposition and voting of the securities.
    PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C., Name: /s/ Phil Frohlich, Title: Managing Member 08/11/2025
    PRESCOTT GROUP AGGRESSIVE SMALL CAP, L.P., By: Prescott Group Capital Management, L.L.C., its general partner, Name: /s/ Phil Frohlich, Title: Managing Member 08/11/2025
    PRESCOTT GROUP AGGRESSIVE SMALL CAP II, L.P., By: Prescott Group Capital Management, L.L.C., its general partner, Name: /s/ Phil Frohlich, Title: Managing Member 08/11/2025
    PRESCOTT GROUP AGGRESSIVE SMALL CAP MASTER FUND, G.P., By: Prescott Group Aggressive Small Cap, L.P., GP, By: Prescott Group Aggressive Small Cap II, L.P., GP, By: Prescott Group Capital Management, L.L.C., GP, Name: /s/ Phil Frohlich, Title: MM 08/11/2025
    /s/ Phil Frohlich 08/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NATR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    SEC Filings

    View All

    SEC Form 10-K filed by Nature's Sunshine Products Inc.

    10-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    3/10/26 5:10:54 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    3/10/26 5:00:59 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nature's Sunshine Products Inc.

    10-Q - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    11/6/25 5:11:13 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson resumed coverage on Nature's Sunshine with a new price target

    DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

    5/7/25 8:37:48 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

    DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

    3/9/22 9:23:08 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency).GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.Adjusted EBITDA up 16% to $11.9 million compar

    3/10/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets Fourth Quarter 2025 Conference Call for Tuesday, March 10, 2026, at 5:00 p.m. ET

    LEHI, Utah, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, March 10, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, March 10, 2026Time: 5:00 p.m. Eastern time

    2/24/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Euromonitor International Names Synergy Pro-Argi-9+ the World's #1 L-Arginine Supplement

    LEHI, Utah, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Synergy Worldwide, a division of Nature's Sunshine Products, today announced that Euromonitor International has named Pro-Argi-9+ the world's #1 l-arginine supplement,* reinforcing the product's growing global momentum and Synergy's leadership in the health and wellness space. Synergy's flagship product, Pro-Argi-9+ offers a unique formula with clinically researched ingredients featuring L-Arginine to support nitric oxide production and promote healthy circulation and blood flow throughout the body. With this certification, Pro-Argi-9+ will continue to serve as the cornerstone of Synergy's mission to help people push the boundaries of their po

    12/15/25 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & President, Europe Yates Bryant J sold $475,215 worth of shares (19,516 units at $24.35), decreasing direct ownership by 19% to 85,154 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    3/17/26 5:11:46 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & President, Asia Norman Daniel C sold $377,191 worth of shares (15,383 units at $24.52) and gifted 3,610 shares, decreasing direct ownership by 27% to 52,083 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    3/17/26 5:10:54 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Accounting Officer Lanoy Jonathan David sold $98,800 worth of shares (4,000 units at $24.70), decreasing direct ownership by 8% to 46,405 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    3/16/26 1:09:05 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Financials

    Live finance-specific insights

    View All

    Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency).GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.Adjusted EBITDA up 16% to $11.9 million compar

    3/10/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets Fourth Quarter 2025 Conference Call for Tuesday, March 10, 2026, at 5:00 p.m. ET

    LEHI, Utah, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, March 10, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, March 10, 2026Time: 5:00 p.m. Eastern time

    2/24/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Strong Third Quarter 2025 Results

    Net Sales up 12% to $128.3 Million, GAAP EPS up 30% to $0.30Adjusted EBITDA up 42% to $15.2 MillionRaised Full-Year Outlook LEHI, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 12% to $128.3 million compared to $114.6 million (up 10% in constant currency).Gross profit margin increased 200 basis points to 73.3% compared to 71.3%.GAAP net income attributable to common shareholders was $5.3 million, o

    11/6/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    View All

    Nature's Sunshine Appoints Erich Fritz as Executive Vice President of Global Supply Chain

    LEHI, Utah, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Erich Fritz has been named Executive Vice President, Global Supply Chain, effective December 8, 2025. Mr. Fritz will report directly to Ken Romanzi, the Company's Chief Executive Officer. Mr. Fritz brings over 40 years of executive experience in operations, supply chain, and business development, with a proven track record of driving growth, operational efficiency, and innovation at leading consumer goods companies. His leadership spans Fortune 500 organizations an

    12/4/25 10:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Kenneth Romanzi as CEO

    Mr. Romanzi Brings Extensive Leadership and Operational Experience at Prominent, Large-Scale Consumer Packaged Goods Companies and Proven Track Record of Driving Growth and Value Creation LEHI, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature's Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with

    10/15/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Announces Leadership Transition Plan

    Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors. The Nature's Sunshine Board ha

    6/2/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/12/24 10:37:49 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    1/31/24 11:56:05 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/13/23 2:42:04 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care